26. November 2019

Transglutaminase conference highlights 2020!

Zedira kits

Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | December 2019

Zedira Calculator

Get your free Zedira Calculator

For all orders until December 31st, 2019!

Dear Transglutaminase researchers,

While 2019 is coming to an end, we are already looking forward to an exciting year 2020 – with top-class conferences:

Microbial transglutaminase users come together from March 2nd to 5th 2020 at the World Antibody Drug Conjugate meeting in London.

 Celiac Disease researchers and clinicians meet even twice: From March 6th to 7th 2020 in New York, USA, with a focus on new therapies, and then again from September 18th to 19th 2020 in Tampere, Finland, where the renowned "Maki Celiac Disease Tampere Prize" will be awarded.

A highlight of the year will certainly be the Gordon Research Conference - "Transglutaminases in Human Disease Processes", taking place from June 14th to 19th 2020 in Mount Snow, Vermont, USA.

The entire transglutaminase community is looking forward to exciting talks of cutting edge research in the transglutaminase field and to meet all the transglutaminase folks personally again.

And of course we at Zedira will continue to support your R&D efforts with our transglutaminase specialty reagents, both in academia and in industry.

Sincerely yours,
On behalf of the entire Zedira team
Martin Hils and Ralf Pasternack

Please have a look on selected products from our broad range of transglutaminase specialty reagents.
You can find more of them and additional information at zedira.com or just by contacting us (contact@zedira.com).

Microbial Transglutaminase, MTG

Art. No. Name Unit Price

T001 Microbial (bacterial) transglutaminase
(MTG, recombinantly produced in E. coli,
gene derived from Streptomyces mobaraensis)
25 U
250 U
10x 25 U
500 U
20x 25 U
270 €
2140 €
2140 €
3750 €
3750 €

ZediXclusive Microbial Transglutaminase Assay Kit
Determination of microbial transglutaminase activity

1 Kit 310 €
Polyclonal antibody to microbial transglutaminase
Microbial transglutaminase (T001), raised in mouse

200 µg 365 €
Inhibition of microbial transglutaminase, IC50 ~ 125 μM
10 mg
25 mg
210 €
385 €

Neuronal Transglutaminase, TG6

Now part of the European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders (Al-Toma et al., 2019).

Art. No. Name Unit Price


ZediXclusive TG6-ab ELISA (IgA)
ELISA for the determination of autoantibodies (IgA) against human Transglutaminase 6
1 kit/
96 wells 
520 €
ZediXclusive TG6-ab ELISA (IgG)
ELISA for the determination of autoantibodies (IgG) against human Transglutaminase 6

1 kit/
96 wells 
520 €
T021 Human neuronal transglutaminase
(TG6, recombinantly produced in insect cells)

250 µg 475 €

Tissue Transglutaminase, TG2

Art. No. Name Unit Price

T022 Human tissue transglutaminase
(hTG2, recombinantly produced in insect cells)

250 µg
1 mg
370 €
1100 €
Tissue Transglutaminase Pico-Assay Kit
Determination of tissue transglutaminase activity

1 Kit 395 €
FITC-labeled polyclonal antibody to human TG2
A014 purified via affinity chromatography on protein A, followed by FITC-labeling

200 µg 395 €
Z-DON-Val-Pro-Leu-OMe, „Z-DON“ 
Irreversible inhibitor of tissue transglutaminase
10 mg 385 €

Coagulation Factor XIII, FXIII

Art. No. Name Unit Price

T027 Human blood coagulation Factor XIII-A2
(hFXIII, A subunit, recombinantly produced in insect cells) 

200 µg 370 €
T070 Human Factor XIIIa, Thrombin activated
(hFXIIIa, recombinantly produced in insect cells)

200 µg 520 €

FXIII-Assay Kit
Ready to use, contains FXIII-Assay Substance (A101) and thrombin
Fluorescent measurement of transglutaminase activity, optimized for FXIII

1 Kit 575 €
Site specific irreversible inhibitor of plasma transglutaminase
5 mg 480 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA